303 related articles for article (PubMed ID: 12415062)
1. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
Lainka E; Oezbek S; Falck M; Ndagijimana J; Niehues T
Pediatrics; 2002 Nov; 110(5):e56. PubMed ID: 12415062
[TBL] [Abstract][Full Text] [Related]
2. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
3. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
4. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors.
Melvin AJ; Lennon S; Mohan KM; Purnell JQ
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1117-23. PubMed ID: 11522181
[TBL] [Abstract][Full Text] [Related]
5. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
[TBL] [Abstract][Full Text] [Related]
6. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
[TBL] [Abstract][Full Text] [Related]
7. Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children.
Hazra R; Cohen RA; Gonin R; Monteiro JP; Hofer CB; Negra MD; Ruz NP;
AIDS; 2012 Jan; 26(2):235-40. PubMed ID: 22008654
[TBL] [Abstract][Full Text] [Related]
8. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
9. Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women.
Floris-Moore M; Howard AA; Lo Y; Arnsten JH; Santoro N; Schoenbaum EE
HIV Med; 2006 Oct; 7(7):421-30. PubMed ID: 16925727
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
[TBL] [Abstract][Full Text] [Related]
11. Relative effects of insulin resistance and protease inhibitor treatment on lipid and lipoprotein metabolism in HIV-infected patients.
Beatty G; Chu J; Kulkarni K; Lipshutz G; Khalili M; Abbasi F; Stansell J; Reaven GM
HIV Clin Trials; 2004; 5(6):383-91. PubMed ID: 15682351
[TBL] [Abstract][Full Text] [Related]
12. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
[TBL] [Abstract][Full Text] [Related]
13. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.
Behrens G; Dejam A; Schmidt H; Balks HJ; Brabant G; Körner T; Stoll M; Schmidt RE
AIDS; 1999 Jul; 13(10):F63-70. PubMed ID: 10416516
[TBL] [Abstract][Full Text] [Related]
14. Impact of cocaine use on protease inhibitor-associated dyslipidemia in HIV-infected adults.
Li J; Lai H; Chen S; Lai S
Int J STD AIDS; 2018 Jul; 29(8):781-789. PubMed ID: 29471762
[TBL] [Abstract][Full Text] [Related]
15. Hyperlipidemia in HIV-positive patients receiving antiretrovirals.
Segarra-Newnham M
Ann Pharmacother; 2002 Apr; 36(4):592-5. PubMed ID: 11918504
[TBL] [Abstract][Full Text] [Related]
16. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.
Hatano H; Miller KD; Yoder CP; Yanovski JA; Sebring NG; Jones EC; Davey RT
AIDS; 2000 Sep; 14(13):1935-42. PubMed ID: 10997397
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
18. High frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virus.
Albuquerque EM; de Faria EC; Oliveira HC; Magro DO; Castilho LN
BMC Infect Dis; 2005 Jun; 5():47. PubMed ID: 15955243
[TBL] [Abstract][Full Text] [Related]
19. Dyslipidemia in a cohort of HIV-infected Latin American children receiving highly active antiretroviral therapy.
Brewinski M; Megazzini K; Hance LF; Cruz MC; Pavia-Ruz N; Della Negra M; Ferreira FG; Marques H; Hazra R;
J Trop Pediatr; 2011 Oct; 57(5):324-32. PubMed ID: 20889625
[TBL] [Abstract][Full Text] [Related]
20. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy.
Vergis EN; Paterson DL; Wagener MM; Swindells S; Singh N
Int J STD AIDS; 2001 Jul; 12(7):463-8. PubMed ID: 11394983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
